It is more than 160 yr since the first use of modern anaesthetic agents, but we still do not know their mechanism of action. Recent studies of mechanisms have been predominantly 'target orientated', investigating the activity of general anaesthetics at putative sites of action. 46 81 For example, studies have focused on anaesthetic action at ligand-gated channels in vitro, 32 yet the relevance of these targets in achieving general anaesthesia at clinically relevant concentrations remains uncertain. 18 86 An alternative approach for studying mechanisms of anaesthesia is one that is 'ligand orientated', focusing on the molecular features of the anaesthetics that determine their activity. There is no common sub-structure that determines anaesthetic activity. Structure -activity relationships have been limited to structurally homologous groups of i.v. and volatile agents, with regard to potency, duration of onset and offset, and untoward side-effects. 16 24 28 52 53 However, these studies do not offer any explanation as to why a diverse group of compounds all produce immobilization or anaesthesia; so, there is need to move away from structure per se and focus instead on the physicochemical properties of the molecules that their structures dictate.
For the volatile agents, a number of physicochemical properties have been identified as key in explaining their mechanism of action. 6 The conventional model of inhalation anaesthetic agent action has been based on the Meyer-Overton hypothesis, 45 50 which describes the proportional relationship between the non-polar solubility of the agents and their anaesthetic activity. However, there are a number of volatile compounds that deviate from the Meyer-Overton hypothesis-namely as the transitional agents (which are less potent than predicted by the model) 30 38 39 and the non-anaesthetics or non-immobilizers [which, despite their high lipid solubility, exhibit no immobilizing activity (but do induce the amnesia and oblivion aspect of general anaesthesia)]. Furthermore, the MeyerOverton hypothesis alone cannot account for potency differences observed for stereoisomers (such as enantiomers of the chiral ethers, isoflurane, enflurane, and desflurane in vitro); 19 22 25 29 55 although the importance of stereoisomerism in determining anaesthetic potency in vivo remains controversial. 17 40 The significant relationship between lipid solubility and potency seen with the volatile agents is not generally the case for the i.v. agents, although Angel demonstrated a significant correlation between the concentration of anaesthetic required to decrease the somatosensory-evoked potential response to 50% of the starting level and the membranebuffer partition coefficient in urethane-anaesthetized animals. 3 Similarly, Dodson and colleagues 14 found a correlation between the aqueous concentrations of barbiturates required to produce a loss of righting reflex in tadpoles and their octanol -water partition coefficient (log P). However, log P has been shown to be a poor predictor of anaesthetic activity for both structurally homologous and chemically diverse i.v. general anaesthetics. 33 65 It is also unable to predict the potency order of the enantiomers of chiral anaesthetics such as ketamine. 65 There are in vitro and in vivo studies examining the dynamics and disposition of the stereoisomers of ketamine, etomidate, and some of the barbiturates. However, etomidate and ketamine are the only chiral i.v. hypnotic agents where single enantiomers are presently used clinically, and where there is evidence of potency differences between the isomers. 21 59 60 78 84 85 Thiopental, thiamylal, and methohexital are all administered as racemic mixtures, but there are differences in potency of the enantiomers in vitro, and in their kinetics in vivo. The fundamental problem with conventional descriptors such as non-polar solubility and log P is that they represent three-dimensional molecular properties as onedimensional parameters. This problem can be overcome by using computer-based molecular modelling techniques.
Molecular similarity studies
Studies by Sewell and Halsey 63 64 have previously described the use of computer-modelling techniques to demonstrate that shape similarity indices were the best predictors for the potency within two homologous series of volatile anaesthetic compounds, namely substituted fluoroethanes and ethers. When activity relationships were calculated for 18 substituted fluoroethane and ether inhalation anaesthetics, there was a better correlation between potency and shape similarity when compared with the correlation with olive oil/gas solubility (the ranges of the correlation coefficients being 0.939 -0.984 compared with 0.005-0.512, respectively). The predictive ability of these models, determined by cross-validation, was also significantly higher than that of the conventional lipid solubility model, and of relationships based on van der Waals surface areas 63 ( Fig. 1) . In a second study, they used the same methodology to attempt the identification of anaesthetic and nonanaesthetic molecules based on their shape and electrostatic potentials (which represents the distribution of charge around a molecule as a result of different electron affinities of its constituent atoms). 64 They derived a model based on a data set of 89 volatile agents (including halogenated alkanes, cycloalkanes, ether, and aromatic compounds) of varying size between 1 and 10 carbon atoms in length. After assignment of all the agents to one of three activity classes (conventional anaesthetic; transitional agent; and non-immobilizer) depending on whether they followed or deviated from the classical non-polar solubility model of action, the respective Carbo shape and Hodgkin electrostatic potential indices were calculated. Using discriminant analysis, a model was formulated based on a weighted combination of some of the similarity variables. Only 14 of 178 variables were used in the final model, which showed that 97.8% of the agents were assigned to their correct activity class. When the predictive power of the model was tested, the similarity model Fig 1 Correlation between observed anaesthetic potencies and values predicted using (A) olive oil/gas partition coefficients and (B) the shape similarity model for a series of ethers. It can be seen that not only does the shape similarity model improve the potency predictions of the conventional anaesthetics, but it also accurately predicts the activities of the transitional agents and the potency order for the enantiomers of isoflurane-two areas where the non-polar solubility model fails. (Reproduced, with permission from the editor and publishers, from reference 63.)
Studies on the mechanisms of anaesthesia using a physicochemical approach correctly assigned 94.4% of 'unknown' agents to their correct activity class.
All 24 non-anaesthetics were correctly predicted to be inactive; of the 33 conventional anaesthetics, 1 was incorrectly predicted to be a transitional agent, and of the 32 transitional agents, 1 was predicted to be non-anaesthetic. When modelled into one of the three groups based on olive oil -gas solubility, only 44.9% were corrected assigned to the appropriate activity class with a q 2 of 0.438 during cross-validation. 64 Trogdon and colleagues 80 have also highlighted the importance of electrostatic potential in determining volatile anaesthetic potency.
Intravenous agents
Using 'molecular similarity modelling', we derived a model based on alignment by shape and electrostatic potential, generating an 'all-in model' using data available for 11 different and diverse i.v. agents. 65 Based on the literature data and unpublished data from the author, the plasma free drug concentrations associated with lack of response to noxious stimulation in 50% of subjects was obtained for 11 diverse i.v. anaesthetic agents (eltanolone, minaxolone, thiamylal, thiopental, methohexital, R(2)-ketamine, R-etomidate, Althesin as alphaxalone, S(+)-ketamine, pentobarbital and propofol).
Low-energy conformers of each anaesthetic were identified and geometry optimized using semi-empirical quantum mechanics (MOPAC 6, Quantum Chemistry Program Exchange, Bloomington, IN, USA). The conformers of the most potent compound, eltanolone (5b-pregnanolone) were nominated as lead structures and used as alignment templates for other agents. The anaesthetics were rotated and aligned so as to maximize their similarity to the lead structures. Similarities in molecular shape and electrostatic potential were calculated using Carbo and Hodgkin Indices using ASP 3.22 (Accelrys Inc., Cambridge, UK), and correlated with in vivo potency.
The best model obtained was one based on combined molecular shape and electrostatic potential similarities to two low-energy conformers of eltanolone. This model explained 82% of the variance in the observed activities of the 11 hypnotic agents (F 1,9 =41.094; P,0.001, n=11). Cross validation (in which 20% of the compounds were excluded at each stage) showed that the model had intrinsic predictive power (q 2 =0.755). The model correctly predicted the potency order for the enantiomers of the chiral agent ketamine; but identified alphaxalone (the main active component of the steroid Althesin) as a clear outlier, being less potent than would be predicted from its molecular similarity. Exclusion of alphaxalone from the analysis resulted in an improved model (r 2 =0.972), and a high predictive power of 96%. 65 For comparison, when potency was correlated with lipophilicity (expressed as the octanol/water partition coefficient-Log P), the model explained only 64.7% of the variance (F 1,9 =16.531; P,0.003, n=11). Furthermore, this Log P model had low predictive power with a crossvalidated r 2 of 0.418. Why was alphaxalone an outlier in this model? More recent data on the plasma protein binding of alphaxalone suggest that the value determined by Child and colleagues 8 of 37.7% to be an underestimate. The figure of 96.8% reported by Visser and colleagues 82 is more in keeping with the binding of other pregnanes, and was subsequently shown in the next model to improve the fit for alphaxalone.
A second model was then developed using CoMFA (Comparative Molecular Field Analysis) with the SYBYL software package (Tripos Inc., St Louis, MO, USA). While the earlier 'Molecular Similarity Model' aimed to identify global similarities in molecular shape and charge, 65 CoMFA allowed the determination of the relationship between the spatial distribution of these properties and associated in vivo potency. 13 34 The structures are aligned and placed in a grid consisting of lattice points at regular intervals (typically 1 Å ). A probe atom (such as an sp 3 carbon atom) is placed at each of the lattice points, and the steric and electrostatic interaction energies between the probe and the anaesthetic molecules are calculated. Steric energies are calculated using a Lennard-Jones 6-12 potential, which describes the attraction between molecules because of van der Waals forces (dispersion, dipole-induced dipole, and dipole-dipole interactions) and repulsion because of steric clashes, and electrostatic interaction energies are calculated using Coulomb potentials with a distance-dependent dielectric function. An activity model is formulated using partial least squares (PLS) regression to correlate the interaction energies at each lattice point with the potencies of the anaesthetics.
Data for EC 50 plasma free drug concentrations of 14 i.v. anaesthetic agents were used, with agents being arbitrarily divided into a training set of 10 agents [eltanolone-the most potent of the i.v. hypnotics, minaxolone, ORG 21465 (a water-soluble dimethylmorpholin-4-yl, 5a-pregnane steroid), thiamylal, thiopental, methohexital, R(2)-ketamine, R-etomidate, ORG 25 435 (an a-aminoacid phenolic ester derivative) and clomethiazole] and a test set of four agents (alphaxalone, S(+)-ketamine, pentobarbital, and propofol). The CoMFA similarity indices were then correlated to in vivo potency. 66 The training set CoMFA model explained 94.0% of the observed variance in the compounds (F 1,8 =125.843; P,0.0001, n=10); and showed good intrinsic predictability (q 2 =0.768). The CoMFA model also accurately predicted the potencies of the test set compounds (r 2 =0.799) and also the potency order of the ketamine enantiomers (Fig. 2) .
For these 14 i.v. agents, the relative contributions of electrostatic and steric fields to the overall activity model were approximately equal (50.7 and 49.3%, respectively). Analysis of the individual contributions to the activity model made by the interaction energies at each point in the lattice grid enables the identification of the regions where steric and electrostatic interactions are important in determining activity.
Pharmacophoric maps showing the spatial distribution of these key regions can be derived using isocontours to link lattice points where the product of the standard deviation of the interaction energies and the PLS weighting coefficient at that point exceeded a certain value (Figs 3 and 4). The maps therefore indicate areas where the differences in either the steric or electrostatic interaction energies are highly associated with differences in anaesthetic potency. High negative values indicate areas where either there is a high negative electrostatic potential or the absence of molecular bulk is favoured for high potency; while high positive values show areas where there is either a high positive electrostatic potential or where the presence of molecular bulk is favoured.
The electrostatic pharmacophore map for the i.v. anaesthetic model shows three main areas where a high positive electrostatic potential is favoured (blue areas: A, B and C), and two where a negative potential is favoured (red areas: D and E). If we compare the maps for the lead compound eltanolone and the less potent thiopental, there are fewer regions in the latter where the electrostatic potentials fit the model of the lead compound eltanolone.
In the steric interaction maps, the cut-off values for the isocontours are shown in green for bulk favoured areas, and purple where bulk is disfavoured. If the molecular bulk extends into the latter zone, anaesthetic potency will be reduced. The maps show three centres (E, G, and H) where molecular bulk is favoured; and two areas (I and J) where bulk is disfavoured. Studies on the mechanisms of anaesthesia using a physicochemical approach Again, a molecular model based on the observed or predicted Log P was significantly poorer than the CoMFA model. It explained only 78.3% of the observed activities of the training set (F 1,8 =28.914; P=0.0007, n=10) with a lower intrinsic predictability (q 2 =0.701), and poor extrinsic predictive power (test set r 2 =0.272) (Fig. 5) . Although we have concentrated on developing models for i.v. hypnotic agents, other authors have used similar techniques to derive a 4D-QSAR model for the binding sites for propofol on the GABA A receptor; 33 to derive the sedative -hypnotic pharmacophore for 1-(2-pyrimidinyl) piperazine derivatives;
6 to develop a model explaining structure -activity relationships of m-opiates; 5 the pharmacophore for opioid receptor antagonists; 51 a QSAR study of 4-phenylpiperidine derivatives as m-opioid agonists; 83 CoMFA interaction models of 3-methylfentanyl derivatives with m-opioid receptors; 74 and a novel binding site model for fentanyl at the m-opioid receptor. 71 
Development of pharmacophore maps for different activities of i.v. anaesthetic agents
Using the same modelling technique, we have also derived a preliminary CoMFA model and accompanying pharmacophoric maps for another aspect of i.v. general anaesthetic activity-namely cardiovascular depression. 68 To generate this model, data for the relationship between steady-state drug concentrations (EC 50 free drug concentration that abolished movement in response to noxious stimuli) and cardiovascular depression (measured as the plasma free drug concentration of anaesthetic that decreased mean arterial blood pressure by 20%, dMAP 20 ) were gathered from the literature or unpublished data from the author for 8 i.v. agents [eltanolone; alphaxalone; minaxolone; ORG 21465; thiopental and methohexital (both infused as the racemate); propofol; R-etomidate). Separate CoMFA activity models were formulated for these two aspects of anaesthetic activity using SYBYL v 6.7. The same single lead structure, the conformer of eltanolone used in our previous studies, was retained for both CoMFA models.
The CoMFA model for cardiovascular depression explained 91.8% of the variance in the observed activities of the 8 i.v. anaesthetics (F 1,6 =67.276; P=0.0002). However, the intrinsic predictive capability was limited (q 2 =0.623). When drug concentrations associated with immobility in 50% patients and 20% decrease in mean arterial pressure were compared, there was a significant correlation (r 2 =0.833). Qualitative comparison of the electrostatic and steric pharmacophoric maps for anaesthetic potency and cardiovascular depression also shows a high degree of similarity, with three common positive favoured and one common negative favoured electrostatic areas; and one bulk favoured area that was common to both models ( Fig. 6A and B) . Additional work is needed to develop these models further. However, the similarity of the two models would suggest that it will be difficult to separate those molecular features describing potency (EC 50 ) and cardiovascular depression.
Development of pharmacophores of nonhalogenated and halogenated volatile agents
We have also derived CoMFA models and pharmacophoric maps for structurally diverse inhalation agents. It was necessary to derive separate CoMFA models for nonhalogenated and halogenated agents because of the problem of aligning these two sets of compounds with very different electrostatic profiles using molecular similarity indices (see Sewell and Sear 67 for further discussion). Anaesthetic potency data [defined as the minimum alveolar concentration (MAC) that abolishes movement in response to noxious stimulation in rats] were obtained from the literature for 38 non-halogenated and 69 halogenated chemically diverse volatile anaesthetics (including substituted alkanes, alkenes, alkynes, alcohols, thiols, aromatics, and ethers) of varying sizes. Some volatile anaesthetics were excluded from the analyses. Compounds greater than eight carbon atoms in length (octanol and larger derivatives) were excluded as a result of their molecular flexibility, which would have created an (at that time) unmanageable number of conformers to consider. Nitrous oxide was excluded because of its resonant structure, interchanging between the N=N + -O 2 and N + =N + =O forms, and would require special treatment of its electrostatic field. 20 Inert gases (xenon, etc.) and nitrogen were excluded because they do not possess electrostatic potentials. The non-halogenated and halogenated agents were randomly divided into training sets (used to derive the CoMFA models) and test sets (used to independently assess the models' predictive capability).
For the non-halogenated volatile agents, the anaesthetic structures were aligned so as to maximize their similarities in molecular shape and electrostatic potential to conformers of the most potent agent in the group, hexanol. 67 A random conformational search using SYBYL v 6.7 identified 66 low-energy hexanol conformers, and each of these was used in turn as a separate template for the remaining anaesthetics. Thus, 66 different sets of anaesthetic alignments were obtained-from which 66 individual CoMFA models were derived. The CoMFA model with the greatest predictive capability (assessed using leave-one-out crossvalidation) was retained as the final activity model. The final CoMFA model explained 95.5% of the variance in the observed anaesthetic activity of the training set compounds (F 2,25 =263.529; P,0.0001, n=28) with good intrinsic predictability assessed by leave-one-out cross validation (q 2 =0.824). The CoMFA model was also an accurate predictor of potency for the randomly excluded test set agents (r 2 =0.921, n=10). A comparable procedure was carried out for the halogenated volatile compounds, using CF 2 H-(CF 2 ) 3 -CH 2 OH (the most potent halogenated agent considered) as the lead structure. 69 A total of 88 conformers of CF 2 H -(CF 2 ) 3 -CH 2 OH were used as alignment templates for the CoMFA. The final model explained 94.2% of the variability of the training set compounds (F 4,47 =189.314; P,0.0001, n=52), with adequate intrinsic predictability under cross validation (q 2 =0.705). The model was also an adequate predictor of anaesthetic potency for the randomly excluded test set agents (r 2 =0.837, n=17). The necessity for separate models for the nonhalogenated and halogenated volatile anaesthetics does not imply per se that the molecular basis for their immobilizing activity is different, nor does it imply two separate sites of action. A qualitative comparison of the two pharmacophore maps shows some areas of commonality between the two sets of agents in terms of the relative contributions to each activity model of steric (molecular bulk) and electrostatic interaction energies; however, for the non-halogenated anaesthetics, the electrostatic interactions are more important than the steric interactions in determining in vivo potency (Fig. 7) . For the halogenated agents, electrostatic and steric interaction energies appear to be equally important (steric to electrostatic field ratios were 1:2.9 for the non-halogenated anaesthetics, and 1:1.2 for the halogenated anaesthetics). 67 69 How do our data compare with those of other researchers? Mehdipour 44 based on potency data of Koblin and colleagues. 31 Conformers of the anaesthetics were geometrically optimized using ab initio quantum mechanics (Gaussian 98) and molecular descriptors calculated for the lowest energy conformer were found for each agent. The descriptors included: highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) energies, molecular polarizability (MP) and molecular dipole moment (MDP) calculated using Gaussian 98; quantum chemical indices of hardness, softness, electronegativity, chemical potential, and electrophilicity; atomic partial charges; topological indices calculated using Hyperchem 7 (Hypercube Inc., USA) and olive oil/gas partition coefficients using the data of Koblin and colleagues. 31 The best model obtained was based on a combination of olive oil/gas partition coefficients, MP, the electrostatic potential at the second carbon atom (C2), and the most positive charge (MPC) encountered. This model explained 97% of the variance in the observed activities of the anaesthetics (F=140.5, n=25), and had good intrinsic predictability under leave-one-out cross validation (q Thus, they suggest that the activity of their series of polyhalogenated ethers could be best explained by MP and coulombic interactions, and also hydrophobic interaction.
Abraham and colleagues
Failure to provide a single set of physical or chemical characteristics (e.g. the Meyer -Overton hypothesis) that can accurately predict anaesthetic potency has led to other approaches to physicochemical modelling, including those of Abraham and colleagues. 2 They have recently modelled the potency of volatile anaesthetic agents according to the 'Abraham Solvation Parameter Model' (ASPM). 1 The ASPM is a useful approach for analysing and describing the properties that determine the equilibrium concentration of a volatile compound or solute in the vapour to a condensed or solvent phase. The equation has five independent variables: E: anaesthetic excess molar refraction S: anaesthetic dipolarity ( plus some polarizability) A: anaesthetic hydrogen bond acidity B: anaesthetic hydrogen bond basicity L: solubility of the gaseous anaesthetic in hexadecane at 258C. Hence, Abraham and colleagues propose that there are two main factors responsible for the potency of volatile anaesthetic agents, compound size and compound hydrogen bond acidity. Their model indicates that molecular shape has little or no effect on anaesthetic activity. This appears to be in contrast to the observations of Sewell and Halsey, who found molecular shape to be a good predictor of anaesthetic potency. 63 However, it should be noted that because of the way shape similarity indices are calculated, they actually describe more than shape alone. 7 Shape-similarity indices are really describing similarities in the spatial distribution of molecular bulk. As such, they also indirectly incorporate molecular size in their values.
In a discussion of previously published work into the possible physico-chemical mechanisms of general anaesthesia, Abraham and colleagues suggest that their approach offers significant advantages over our more complex modelling method. It is true that 2D QSAR approaches such as the Abraham solubility model offer a speed and simplicity advantage over 3D QSAR, as a result of 2D QSAR not requiring the consideration of molecular flexibility or the alignment of the structures before analysis (the latter being particularly problematic for CoMFA as we have discussed in our study of halogenated volatile anaesthetics). 73 The question of whether the additional calculation time is warranted depends on the purpose of the study. There are aspects of anaesthetic activity which 2D QSAR approaches cannot easily accommodate, such as the stereospecificity of chiral anaesthetics. As such, it would be interesting to see how well the Abraham solubility model in its current form accommodates the i.v. anaesthetics.
One very important point to note is that Abraham and colleagues 2 in their discussion on mechanisms, state that our use of two CoMFA models for halogenated and non-halogenated anaesthetics represents a mechanism based on two receptors. This is totally incorrect as we have discussed both in this review and in more detail in our two original papers. 67 
69

Concluding remarks
A modelling approach using techniques such as molecular similarity indices or comparative molecular field analysis can be used to show that the activity of structurally diverse anaesthetics can be described by a single model based on spatial distribution of molecular bulk and electrostatic potential. As such, it provides a common molecular basis of activity for diverse anaesthetics. Preliminary data suggest similarity between the molecular bases of immobilizing activity and cardiovascular depression of i.v. anaesthetic agents, such that future pharmaceutical attempts at separation of these two features may be difficult to achieve.
